Market-Moving News for May 6th
$EYPT
$FRPT
$TCBP
Biotechnology: Laboratory Analytical Instruments
Industrials
Packaged Foods
Consumer Staples
Get the next $EYPT alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | ||
| 8/28/2024 | $15.00 | Buy | Jefferies | |
| 5/23/2024 | $150.00 | Buy | Deutsche Bank | |
| 5/23/2024 | $168.00 | Neutral → Buy | Redburn Atlantic | |
| 3/11/2024 | $120.00 → $135.00 | Hold → Buy | Truist | |
| 2/1/2024 | $94.00 | Neutral | Citigroup | |
| 1/22/2024 | $35.00 | Overweight | JP Morgan | |
| 12/19/2023 | $80.00 | Hold | Jefferies |
3 - Freshpet, Inc. (0001611647) (Issuer)
4 - Freshpet, Inc. (0001611647) (Issuer)
4 - Freshpet, Inc. (0001611647) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform
Jefferies initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $15.00
Deutsche Bank initiated coverage of Freshpet with a rating of Buy and set a new price target of $150.00
8-K - Freshpet, Inc. (0001611647) (Filer)
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
SCHEDULE 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Guggenheim's Inaugural Healthcare Innovation ConferenceForum: Fireside ChatDate: Monday, November 11, 2024Time: 2:00 p.m. ET UBS Global Healthcare ConferenceForum: Fireside ChatDate: Wednesday, November 13, 2024Time: 1:15 p.m. PT Jefferies London Healthcare ConferenceForum: Corporate PresentationDate: Tuesday, November 19, 2024Time: 8:00 a.m. GMT B
25th Consecutive Quarter of >25% Year on Year Net Sales Growth Strong Operating Performance Drove Significant Margin Expansion & Cash Generation Company Raises 2024 Net Sales and Adjusted EBITDA Guidance BEDMINSTER, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Freshpet, Inc. ("Freshpet" or the "Company") (NASDAQ:FRPT) today reported financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Compared to Prior Year Period Net sales of $253.4 million, an increase of 26.3%.Net income of $11.9 million, compared to the prior year period net loss of $7.2 million.Gross margin of 40.4%, compared to the prior year period of 33.0%.Adjusted Gross Margin of
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritten public offering of 14,636,363 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,909,090 shares of common stock, at the public offering price of $11.00 per share. Gross proceeds to EyePoint in the offering, before underwriting discounts and estimated expenses of the offering, were approximately $161.0 million.
25th Consecutive Quarter of >25% Year on Year Net Sales Growth Strong Operating Performance Drove Significant Margin Expansion & Cash Generation Company Raises 2024 Net Sales and Adjusted EBITDA Guidance BEDMINSTER, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Freshpet, Inc. ("Freshpet" or the "Company") (NASDAQ:FRPT) today reported financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Compared to Prior Year Period Net sales of $253.4 million, an increase of 26.3%.Net income of $11.9 million, compared to the prior year period net loss of $7.2 million.Gross margin of 40.4%, compared to the prior year period of 33.0%.Adjusted Gross Margin of
SECAUCUS, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Freshpet, Inc. (NASDAQ:FRPT) ("Freshpet" or the "Company") today announced it will report results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 before market open. The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin at 8:00 a.m. ET on Monday, November 4, 2024. To participate on the live call, listeners in North America may dial (877) 407-0792 and international listeners may dial (201) 689-8263. In addition, the call will be broadcast live over the Internet, hosted on the "I
– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in 2024 – – Positive twelve-month data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD continue to demonstrate favorable safety and efficacy – – Phase 2 VERONA trial of DURAVYU in DME fully enrolled with topline data anticipated in Q1 2025 – – $280.2 million of cash and investments on June 30, 2024, with cash runway through Phase 3 wet AMD topline data for DURAVYU in 2026 – WATERTOWN, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative thera
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240238387
Citigroup analyst Thomas Palmer maintains Freshpet (NASDAQ:FRPT) with a Neutral and raises the price target from $124 to $129.
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future
Company strengthens organizational capabilities with the addition of industry leader Nicki Baty Scott Morris will continue to help lead Freshpet as President and Co-Founder BEDMINSTER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Freshpet, Inc. ("Freshpet" or the "Company") (NASDAQ:FRPT) today announced Nicki Baty has been appointed Chief Operating Officer, effective September 1, 2024. Ms. Baty will report directly to Billy Cyr, Chief Executive Officer. Ms. Baty has a strong track record of scaling businesses, having spent nearly 20 years at Colgate-Palmolive where she most recently served as President and General Manager of Hill's Pet Nutrition U.S. She has deep experience in driving trans
Lauri Kien Kotcher to join Freshpet Board of Directors Current Director Lawrence Coben to retire to refresh Board and improve Board diversity SECAUCUS, N.J., April 10, 2024 (GLOBE NEWSWIRE) -- Freshpet, Inc. ("Freshpet" or the "Company") (NASDAQ:FRPT) today announced updates to its Board of Directors (the "Board"). As part of the Board's ongoing refreshment process, Lawrence S. Coben, Ph.D. has announced his retirement, effective April 8, 2024, and Lauri Kien Kotcher has been appointed to the Company's Board, effective April 9, 2024. Ms. Kien Kotcher will replace Dr. Coben on the Board's Nominating and Governance Committee. Ms. Kien Kotcher brings over three decades of operational and l